FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807513250> ?p ?o ?g. }

• W2807513250 endingPage "68" @default.
• W2807513250 startingPage "56" @default.
• W2807513250 abstract "Immunotherapeutic Agents for SLE Epratuzumab in SLEDavid M Goldenberg & Daniel J WallaceDavid M GoldenbergDavid M Goldenberg is President and Founder of the Center for Molecular Medicine and Immunology (CMMI), and has been an Associate or Full Professor at seven medical schools (University of Pittsburgh, Temple University, University of Kentucky, University of Medicine and Dentistry of New Jersey, and New York Medical College) during his past 42 years in medical research, focusing on cancer biology and immunology, and more recently on B-cell immunotherapy for autoimmune diseases. He has published over 650 peer-reviewed original articles, 80 book chapters, edited two books and 13 journal supplements, and presented over 960 abstracts at national and international meetings. As Chairman and Founder of Immunomedics, Inc., he led the development of epratuzumab, labetuzumab, veltuzumab, milatuzumab, several bispecific antibodies and immunocytokines, and has received awards for pioneering the development of immunoscintigraphy and radioimmunotherapy, including the 2005 Paul C Aebersold Award for Outstanding Achievements in Basic Science Applied to Nuclear Medicine from the Society of Nuclear Medicine.Search for more papers by this author & Daniel J WallaceDaniel J Wallace is a Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA based at Cedars-Sinai Medical Center in Los Angeles (CA, USA). He is the editor of Dubois’ Lupus Erythematosus and author of 290 articles, 20 book chapters and six textbooks. He follows a cohort of over 1000 lupus patients and conducts clinical trials.Search for more papers by this authorPublished Online:23 Feb 2012https://doi.org/10.2217/ebo.11.86AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: This chapter summarizes the current status of the use of epratuzumab, the only anti-CD22 humanized monoclonal antibody (mAb) being studied clinically in the treatment of systemic lupus erythematosus. The role of B cells and their markers is discussed, particularly as targets for therapy of autoimmune disease, and the construction and properties of epratuzumab are described. Finally, a summary is presented of three clinical trials, one involving a small Phase II trial of epratuzumab in systemic lupus erythematosus patients and the other two constituting larger multicenter trials, all using changes in British Isles Lupus Activity Group scores. Bibliography1 Dörner T , Jacobi AM , Lipsky PE . B cells in autoimmunity . Arthritis Res. Ther. 11 (5) , 247 (2009) . Crossref, Medline, Google Scholar2 Goldenberg DM . Epratuzumab in the therapy of oncological and immunological diseases . Expert Rev. Anticancer Ther. 6 (10) , 1341 – 1353 (2006) . Crossref, Medline, CAS, Google Scholar3 Perosa F , Prete M , Racanelli V , Dammacco F . CD20-depleting therapy in autoimmune diseases: from basic research to the clinic . J. Intern. Med. 267 (3) , 260 – 277 (2010) . Crossref, Medline, CAS, Google Scholar4 Thanou-Stavraki A , Sawalha AH . An update on belimumab for the treatment of lupus . Biologics 5 , 33 – 43 (2011) . Medline, CAS, Google Scholar5 Dörner T , Goldenberg DM . Targeting CD22 as a strategy for treating systemic autoimmune diseases . Ther. Clin. Risk Manag. 3 (5) , 953 – 959 (2007) . Medline, Google Scholar6 Traczewski P , Rudnicka L . Treatment of systemic lupus erythematosus with epratuzumab . Br. J. Clin. Pharmacol. 71 (2) , 175 – 182 (2011) . Crossref, Medline, CAS, Google Scholar7 Wilson GL , Fox CH , Fauci AS , Kehrl JH . CDNA cloning of the B-cell membrane protein CD22: a mediator of B-B cell interactions . J. Exp. Med. 173 , 137 – 146 (1991) . Crossref, Medline, CAS, Google Scholar8 Engel P , Wagner N , Miller A , Tedder TF . Identification of the ligand binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand . J. Exp. Med. 181 , 1581 – 1586 (1995) . Crossref, Medline, CAS, Google Scholar9 Wilson GL , Najfeld V , Kozlow E et al. Genomic structure and chromosomal mapping of the human . CD22 gene. J. Immunol. 150 , 5013 – 5024 (1993) . Medline, CAS, Google Scholar10 Dörken B , Moldenhauer G , Pezzutto A et al. Hd39 (B3), a B-lineage-restricted antigen whose cell-surface expression is limited to resting and activated human lymphocytes-B . J. Immunol. 136 , 4470 – 4479 (1986) . Medline, CAS, Google Scholar11 Nitschke L . The role of CD22 and other inhibitory co-receptors in B-cell activation . Curr. Opin. Immunol. 17 , 290 – 297 (2005) . Crossref, Medline, CAS, Google Scholar12 Tedder TF , Poe JC , Haas KM . CD22: A multifunctional receptor that regulates B-lymphocyte survival and signal transduction . Adv. Immunol. 88 , 1 – 50 (2005) . Crossref, Medline, CAS, Google Scholar13 Doody GM , Justement LB , Delibrias CC et al. A role in B-cell activation for CD22 and the protein-tyrosine-phosphatase Shp . Science 269 , 242 – 244 (1995) . Crossref, Medline, CAS, Google Scholar14 Chaouchi N , Vazquez A , Galanaud P , Leprince C . B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking . J. Immunol. 154 , 3096 – 3104 (1995) . Medline, CAS, Google Scholar15 Tuscano JM , Riva A , Toscano SN , Tedder TF , Kehrl JH . CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade . Blood 94 , 1382 – 1393 (1999) . Crossref, Medline, CAS, Google Scholar16 Stein R , Belisle E , Hansen HJ et al. Epitope specificity of the anti-(B-cell lymphoma) monoclonal antibody, LL2 . Cancer Immunol. Immunother. 37 , 293 – 298 (1993) . Crossref, Medline, CAS, Google Scholar17 Pawlak-Byczkowska EJ , Hansen HJ , Dion AS et al. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma . Cancer Res. 49 , 4568 – 4577 (1989) . Medline, CAS, Google Scholar18 Shih LB , Lu HHZ , Xuan H et al. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2 . Int. J. Cancer 56 , 538 – 545 (1994) . Crossref, Medline, CAS, Google Scholar19 Carnahan J , Wang P , Kendall R et al. Epratuzumab, a humanized monoclonal anatibody targeting CD22: characterization of in vitro properties . lin. Cancer Res. 9 , 3982S – 3990S (2003) . Medline, CAS, Google Scholar20 Carnahan J , Stein R , Qu ZX et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab . Mol. Immunol. 44 , 1331 – 1341 (2007) . Crossref, Medline, CAS, Google Scholar21 Stein R , Qu ZX , Chen S . et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma . Clin. Cancer Res. 10 , 2868 – 2878 (2004) . Crossref, Medline, CAS, Google Scholar22 Dörner T , Kaufmann J , Wegener WA . et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus . Arthritis Res. Ther. 8 (3) , R74 (2006) . Crossref, Medline, Google Scholar23 Jacobi , AM , Goldenberg DM , Hiepe F . et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls . Ann. Rheum. Dis. 67 (4) , 450 – 457 (2008) . Crossref, Medline, CAS, Google Scholar24 Daridon C , Blassfeld D , Reiter K et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus . Arthritis Res. Ther. 12 (6) , R204 (2010) . Crossref, Medline, Google Scholar25 Petri M , Hobbs K , Gordon C et al. Randomized controlled trials of epratuzumab (anti CD22 MAB targeting B cells) reveal clinically meaningful improvements in patients with moderate/severe flares . Ann. Rheum. Dis. 67 (Suppl. 2) , 53 (2008) . Google Scholar26 Wallace D , Hobbs K , Houssiau F et al. Randomized controlled trials of epratuzumab (anti CD22 MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients . Ann. Rheum. Dis. 67 (Suppl. 2) , 212 (2008) . Medline, Google Scholar27 Strand V , Gordon C , Kalunian K et al. Randomized controlled trials of epratuzumab (anti-CD22 MAB targeting B-cells) show meaningful improvements in health related quality of life (HRQOL) in SLE patients with high disease activity and low baseline self-report measures . Ann. Rheum. Dis. 67 (Suppl. 2) , 212 (2008) . Medline, Google Scholar28 Wallace DJ , Kalunian KC , Petri MA et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a Phase IIb study . Arthritis Rheum. 62 (Suppl. 10) , 1452 (2010) . Google Scholar29 Kalunian KC , Wallace DJ , Petri MA et al. BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM, a Phase III study . Arthritis Rheum. 62 (Suppl. 10) , 453 (2010) . Google ScholarWebsite101 US National institutes of Health. www.clinicaltrials.gov Google ScholarFiguresReferencesRelatedDetailsCited ByTen Developments in the Use of Biologicals for Systemic Lupus Erythematosus12 May 2013 | Current Rheumatology Reports, Vol. 15, No. 7 Immunotherapeutic Agents for SLEMetrics Downloaded 13 times History Published online 23 February 2012 Published in print February 2012 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2807513250 created "2018-06-13" @default.
• W2807513250 creator A5003890903 @default.
• W2807513250 creator A5071430304 @default.
• W2807513250 date "2012-02-01" @default.
• W2807513250 modified "2023-09-26" @default.
• W2807513250 title "Epratuzumab in SLE" @default.
• W2807513250 cites W1514197537 @default.
• W2807513250 cites W1517715266 @default.
• W2807513250 cites W1532425407 @default.
• W2807513250 cites W1537473321 @default.
• W2807513250 cites W1759864921 @default.
• W2807513250 cites W188330949 @default.
• W2807513250 cites W1944128175 @default.
• W2807513250 cites W1971059031 @default.
• W2807513250 cites W1974078366 @default.
• W2807513250 cites W2022596631 @default.
• W2807513250 cites W2030793757 @default.
• W2807513250 cites W2035000560 @default.
• W2807513250 cites W2041971758 @default.
• W2807513250 cites W2046762204 @default.
• W2807513250 cites W2054409932 @default.
• W2807513250 cites W2075665372 @default.
• W2807513250 cites W2075823688 @default.
• W2807513250 cites W2084146339 @default.
• W2807513250 cites W2107586631 @default.
• W2807513250 cites W2113311041 @default.
• W2807513250 cites W2115608334 @default.
• W2807513250 cites W2118475498 @default.
• W2807513250 cites W2140433336 @default.
• W2807513250 cites W2166580479 @default.
• W2807513250 cites W2166946264 @default.
• W2807513250 doi "https://doi.org/10.2217/ebo.11.86" @default.
• W2807513250 hasPublicationYear "2012" @default.
• W2807513250 type Work @default.
• W2807513250 sameAs 2807513250 @default.
• W2807513250 citedByCount "1" @default.
• W2807513250 countsByYear W28075132502013 @default.
• W2807513250 crossrefType "other" @default.
• W2807513250 hasAuthorship W2807513250A5003890903 @default.
• W2807513250 hasAuthorship W2807513250A5071430304 @default.
• W2807513250 hasConcept C41008148 @default.
• W2807513250 hasConcept C70721500 @default.
• W2807513250 hasConcept C86803240 @default.
• W2807513250 hasConceptScore W2807513250C41008148 @default.
• W2807513250 hasConceptScore W2807513250C70721500 @default.
• W2807513250 hasConceptScore W2807513250C86803240 @default.
• W2807513250 hasLocation W28075132501 @default.
• W2807513250 hasOpenAccess W2807513250 @default.
• W2807513250 hasPrimaryLocation W28075132501 @default.
• W2807513250 hasRelatedWork W2130043461 @default.
• W2807513250 hasRelatedWork W2350741829 @default.
• W2807513250 hasRelatedWork W2358668433 @default.
• W2807513250 hasRelatedWork W2376932109 @default.
• W2807513250 hasRelatedWork W2382290278 @default.
• W2807513250 hasRelatedWork W2390279801 @default.
• W2807513250 hasRelatedWork W2748952813 @default.
• W2807513250 hasRelatedWork W2899084033 @default.
• W2807513250 hasRelatedWork W3004735627 @default.
• W2807513250 hasRelatedWork W2530322880 @default.
• W2807513250 isParatext "false" @default.
• W2807513250 isRetracted "false" @default.
• W2807513250 magId "2807513250" @default.
• W2807513250 workType "other" @default.